Insights on the Cancer/Tumor Profiling Global Market to 2027 – Featuring Caris Life Sciences, Illumina and Qiagen Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Cancer/Tumor Profiling – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering.

Amid the COVID-19 crisis, the global market for Cancer/Tumor Profiling estimated at US$6.2 Billion in the year 2020, is projected to reach a revised size of US$11.6 Billion by 2027, growing at a CAGR of 9.3% over the analysis period 2020-2027.

Immunoassays, one of the segments analyzed in the report, is projected to record a 9.1% CAGR and reach US$3.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Hybridization segment is readjusted to a revised 9.7% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1.8 Billion, While China is Forecast to Grow at 8.7% CAGR

The Cancer/Tumor Profiling market in the U.S. is estimated at US$1.8 Billion in the year 2020. China, the world’s second largest economy, is forecast to reach a projected market size of US$2 Billion by the year 2027 trailing a CAGR of 8.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.5% and 7.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.6% CAGR.

Next Generation Sequencing Segment to Record 10.1% CAGR

In the global Next Generation Sequencing segment, USA, Canada, Japan, China and Europe will drive the 10.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$864.8 Million in the year 2020 will reach a projected size of US$1.7 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.3 Billion by the year 2027.

Select Competitors (Total 44 Featured):

• Caris Life Sciences
• Genomic Health, Inc.
• Helomics Corporation
• HTG Molecular Diagnostics, Inc.
• Illumina, Inc.
• Nanostring Technologies, Inc.
• NeoGenomics Laboratories, Inc.
• Oxford Gene Technology
• Qiagen NV
• Ribomed Biotechnologies, Inc.

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• Influencer Market Insights
• World Market Trajectories
• Impact of Covid-19 and a Looming Global Recession
• Cancer/Tumor Profiling: Market Overview & Outlook
• Impact of Covid-19 and a Looming Global Recession
• Increasing Incidence of Cancer Worldwide: Primary Growth Driver
• The United States: Characterized by Higher Incidence of Cancer
• Enhanced Use of Biomarkers in Tumor Profiling Bodes Well
• Cancer Research & Funding Initiatives Augment Market Prospects
• Growing Role of Personalized Medicine Augurs Well
• Advances in Point-of-Care Cancer Diagnostics to Accelerate Uptake

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/1jqtk7

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

This is a syndicated feed and is brought to you in partnership with Business Wire. Health Insurance Bulletin and Trade News Network are not responsible for any claims made in this story.